Application of SHC1 in urine or urine exosome and polypeptide fragment of SHC1 in type 2 diabetic nephropathy
By detecting SHC1 and its peptide fragments in urine or urine exosomes, the non-invasive and fast problem of type 2 diabetes nephropathy examination was solved, and the accurate diagnosis and condition monitoring of type 2 diabetes nephropathy was achieved, and the quality of life of patients was improved.
Patent Information
- Application Number
- CN202310492739.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-05
- Publication Date
- 2024-11-05
AI Technical Summary
The prior art is difficult to provide a non-invasive, convenient, fast and repetitive type 2 diabetes nephropathy examination method, which leads to frequent blood draws, and the condition is highly concealed, resulting in poor diagnosis.
By studying SHC1 and its peptide fragments in urine or urine exosomes, we developed detection preparations for type 2 diabetic nephropathy, and used immune methods and mass spectrometry technology to construct a urinary exosome map and screen out the differential protein SHC1 and its Polypeptide fragments are used for differential diagnosis, condition judgment, therapeutic effect evaluation and prognosis evaluation.
A non-invasive, rapid and repetitive type 2 diabetes nephropathy detection has been achieved, which improves the accuracy of diagnosis and the quality of life of patients, and reduces unnecessary pain and social burden.
Smart Images

Figure CN118897084A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to new uses of SHC1 and polypeptide fragments thereof in urine or urine exosomes, and specifically to the use of SHC1 and polypeptide fragments thereof in urine or urine exosomes in preparations for differential diagnosis of type 2 diabetic nephropathy, judgment of disease severity, evaluation of treatment effects, monitoring, prognosis assessment and mechanism research. Background Art
[0002] Type 2 diabetic nephropathy is a metabolic endocrine disease characterized by glucose and fat metabolism disorders and increased plasma glucose levels, caused by the combined effects of genetic and environmental factors. In recent years, the incidence of type 2 diabetic nephropathy in the global population has increased rapidly, and has become the most challenging global health problem in the 21st century. With the improvement of living standards and changes in lifestyles, the incidence of type 2 diabetic nephropathy in my country has shown a rapid upward trend. Statistics show that the number of type 2 diabetic nephropathy patients in my country currently ranks second in the world, and it is estimated that by 2040, the number of people with type 2 diabetic nephropathy in China will reach 642 million.
[0003] Hyperglycemia in type 2 diabetic nephropathy can lead to metabolic disorders of carbohydrates, proteins, and fats, thereby causing complications in multiple systems such as nerves, kidneys, and cardiovascular diseases, all of which pose a huge hidden danger to public health. The onset of type 2 diabetic nephropathy is relatively hidden, and most patients are not discovered in time, and are often diagnosed only after the clinical manifestations of complications appear. In addition, patients with type 2 diabetic nephropathy have a long course of disease and need long-term or even lifelong blood sugar monitoring. Repeated blood draws and invasive examinations cause many inconveniences to patients. However, if patients with type 2 diabetic nephropathy are not given timely diagnosis and treatment, multiple organ damages often occur throughout the body as the disease progresses, and severe cases may even become disabled or die due to complications. In summary, type 2 diabetic nephropathy not only causes inconvenience and pain to patients, but also brings a heavy burden to patients' families and society. In order to improve the quality of life of patients with type 2 diabetic nephropathy and solve the practical problems of patients, it is extremely necessary to study a non-invasive, convenient, fast, and easy-to-repeat method for type 2 diabetic nephropathy examination.
[0004] SHC1 is a transmembrane receptor protein tyrosine kinase adapter protein that participates in biological processes such as activating MAPK, regulating cell growth, regulating epidermal growth factor receptor, intracellular signal transduction cascades, positively regulating cell proliferation, and positively regulating mitosis.
[0005] Compared with commonly used clinical blood samples, urine can be collected completely non-invasively, continuously, and in large quantities; without homeostatic regulation, it can accumulate more types and larger changes, and many pathological and physiological changes of the body may be reflected in urine. Some relatively small molecular weight protein peptides such as hormones and cytokines will be quickly excreted into urine after entering the blood. The probability of these proteins and peptides being detected in urine is much greater than in blood; before urine is collected, the possible protein degradation process in urine has been completed, so urine protein can remain stable for a long time. Urine usually contains some epithelial cells and blood cells, bacteria, viruses and important exosomes. Since the discovery of urinary exosomes, studies have pointed out that urinary exosomes can be used as a new biomarker reflecting the physiological and pathological physiological state of the human body. More and more studies have shown that exosomes are involved in the pathological and physiological processes related to DN, which may provide new biomarkers and therapeutic targets for DN patients. In order to alleviate the pain of multiple blood draws for patients with type 2 diabetic nephropathy, this experiment, based on previous methodological exploration, hopes to use urine or urine exosome protein or peptide research to achieve painless, convenient, fast and easy-to-repeat urine testing to assist in the diagnosis and disease monitoring of patients with type 2 diabetic nephropathy. Summary of the invention
[0006] The object of the present invention is to provide an application of SHC1 and its polypeptide fragments in urine or urine exosomes in the preparation of preparations for differential diagnosis, disease severity judgment, treatment effect evaluation, monitoring, prognosis assessment and mechanism research of type 2 diabetic nephropathy.
[0007] Preferably, the amino acid sequence of SHC1 in the urine or urine exosomes includes the amino acid sequence shown in SEQ ID NO.1 (1 mslchrwrsn lkfagmpitl tvstsslnlm aadckqiian hhmqsisfas ggdpdtaeyv 61 ayvakdpvnq rachilecpe glaqdvisti gqafelrfkq ylrnppklvt phdrmagfdg 121 sawdeeeeep pdhqyyndfp gkepplggvv dmrlregaap gaarptapna qtpshlgatl 181 pvgqpvggdp evrkqmpppp pcpgrelfdd psyvnvqnld karqavggag ppnpaingsa 241 prdlfdmkpf edalrvpppp qsvsmaeqlr gepwfhgkls rreaeallql ngdflvrest 301 ttpgqyvltg lqsgqpkhll lvdpegvvrt kdhrfesvsh lisyhmdnhl piisagselc 361 lqqpverkl); Or an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO.1 and having the same function as the amino acid sequence shown in SEQ ID NO.1.
[0008] Preferably, the preparation is a kit for detecting SHC1 and its polypeptide fragments in urine or urine exosomes of patients with type 2 diabetic nephropathy.
[0009] Preferably, the kit includes one or more of an immunological method for antigen-antibody reaction and a kit thereof, such as an aptamer antibody or antibody fragment that can specifically bind to SHC1 and its polypeptide fragments.
[0010] Preferably, the detection method includes mass spectrometry and other methods for directly detecting SHC1 and its polypeptide fragments and related kits.
[0011] Preferably, the detection method includes methods such as direct detection of SHC1 and related nucleic acid detection of its polypeptide fragments and related kits.
[0012] Preferably, the kit further comprises components selected from the following group: any one or a combination of solid phase carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, second antibody, second antibody diluent, luminescent reagent, washing solution, color developing solution and stop solution.
[0013] Preferably, the standard substances include SHC1 standard substances and humanized tag antibody standard substances; preferably, the quality control substances include: SHC1 quality control substances and humanized tag antibody quality control substances; preferably, the solid phase carrier includes: microparticles, microspheres, glass slides, test strips, plastic beads, liquid chips, microplates or affinity membranes, etc. and other carriers with equivalent functions.
[0014] Preferably, the material of the solid phase carrier is any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose, and carriers with similar functions.
[0015] The inventors first collected urine specimens from patients with type 2 diabetes without nephropathy and type 2 diabetic nephropathy, extracted urine exosomes according to the standard operating procedures of the Human Urine Proteome Project (HKUPP) and the European Kidney and Urine Proteomics (EuroKUP), identified urine exosomes by transmission electron microscopy, exosome nanoparticle tracking detection and protein immunoblotting, established urine exosome profiles of patients with type 2 diabetes without nephropathy and type 2 diabetic nephropathy by liquid chromatography tandem mass spectrometry (LC-MS / MS), and processed the data by quantitative value correction / calculation of absolute quantitative value, differential analysis and global clustering analysis of target proteins using data-independent acquisition (DIA) scanning mode. The data obtained in the mass spectrometry of the type 2 diabetes without nephropathy and type 2 diabetic nephropathy groups were quantitatively calculated, and finally the differential protein SHC1 was obtained.
[0016] The present invention confirms through research that compared with patients with type 2 diabetes without nephropathy, SHC1 and its polypeptide fragments in urine or urine exosomes are highly expressed in patients with type 2 diabetic nephropathy, which is consistent with the clinical diagnosis. Therefore, it is proposed that the detection of SHC1 and its polypeptide fragments in urine or urine exosomes can be used for the differential diagnosis, disease severity judgment, treatment effect evaluation, monitoring, prognosis assessment and mechanism research of type 2 diabetic nephropathy.
[0017] The present invention takes advantage of the non-invasive acquisition of urine specimens, large-scale repeated sampling, and convenient storage, and uses urine specimens to detect SHC1 and its polypeptide fragments in urine or urine exosomes.
[0018] In order to make the above and other purposes, features and advantages of the present invention more obvious and easy to understand, preferred embodiments are given below and described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is the content of SHC1 and its polypeptide fragments in urine or urine exosomes in healthy people, type 2 diabetes without nephropathy, and type 2 diabetic nephropathy groups. (T2DN-type 2 diabetes without nephropathy group; DN-type 2 diabetic nephropathy group) Implementation
[0020] Example 1 Urine specimen collection and processing Patients with type 2 diabetes without nephropathy and type 2 diabetic nephropathy were selected as subjects. Fresh morning urine samples were collected from each group of subjects after admission and placed in a dry, clean container. Exosomes were extracted from concentrated urine samples according to the standard operating procedures of HKUPP and EuroKUP (http: / / www.eurokup.org), resuspended in precooled PBS, and stored in a -80°C refrigerator. Urinary exosomes were identified by transmission electron microscopy, exosome nanoparticle tracking detection, and protein immunoblotting.
[0021] Example 2 Mass spectrometry analysis of urine exosome peptides The urine samples were subjected to protein extraction and enzymatic desalination, and the extracted protein concentration was measured. The urine exosome protein profiles of the three groups of subjects were constructed using advanced liquid chromatography-mass spectrometry (LC-MS / MS) and data-independent scanning mode (DIA).
[0022] Example 3 Differential peptide data analysis All experiments were performed three times, and all values are expressed as mean ± standard deviation. The analysis results of differentially expressed proteins were obtained by fold change 1.5 times. P A value <0.05 was considered statistically significant, and differentially expressed proteins were screened, and global cluster analysis was performed on the target proteins.
[0023] Example 4 Validation of SHC1 in urine or urine exosomes Compared with patients with type 2 diabetes without nephropathy, SHC1 in urine or urinary exosomes is highly expressed in patients with type 2 diabetic nephropathy, such as Figure 1 As shown, there is a significant difference in expression.
[0024] Although the present invention has been disclosed as above in terms of preferred embodiments, it is not intended to limit the present invention. Any technician in the relevant technical field may make some changes and improvements without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention shall be based on what is defined in the claims.
Claims
1. Application of SHC1 and its polypeptide fragments in urine or urine exosomes in the preparation of preparations for differential diagnosis, disease severity assessment, treatment effect evaluation, monitoring, prognosis assessment and mechanism research of type 2 diabetic nephropathy.
2. The use according to claim 1, characterized in that: The amino acid sequence of SHC1 in the urine or urine exosomes is shown in SEQ ID NO.1; The use according to claim 1, characterized in that the preparation is a kit for detecting SHC1 and its polypeptide fragments in urine or urine exosomes of patients with type 2 diabetic nephropathy.
3. The use according to claim 3, characterized in that: The kit includes an immunization method for antigen-antibody reaction and a kit thereof, such as one or more of aptamer antibodies or antibody fragments that can specifically bind to SHC1 and its polypeptide fragments.
4. The use according to claim 3, characterized in that: The detection method includes a mass spectrometry method for directly detecting SHC1 and its polypeptide fragments and related kits.
5. The use according to claim 3, characterized in that: The detection method includes methods for directly detecting SHC1 and its polypeptide fragments or related nucleic acid detection and related kits.
6. The use according to claim 3, characterized in that: The kit also includes components selected from the following group: any one or a combination of solid phase carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, second antibody, second antibody diluent, luminescent reagent, washing solution, color developing solution, and stop solution.
7. The use according to claim 7, characterized in that: The standards include SHC1 standards and humanized tag antibody standards; Preferably, the quality control products include: SHC1 quality control products, humanized tag antibody quality control products; preferably, the solid phase carrier includes: microparticles, microspheres, glass slides, test strips, plastic beads, liquid chips, microplates or affinity membranes, etc. and other carriers with equivalent functions.
8. The use according to claim 8, characterized in that: The material of the solid phase carrier is any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose and carriers with similar functions.
